StockData
Quoin Pharmaceuticals Ltd. logo

Quoin Pharmaceuticals Ltd. (QNRX) stock

QNRXNasdaqPharmaceutical Preparations
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30
$3.56+0.20 (+5.95%)

Close on Nov 18, 2026Market cap $7.15MP/E –Yield –

Quoin Pharmaceuticals r&d expenses

Research and development expenses are spending on new products and technology.

Quoin Pharmaceuticals's R&D Expenses for the twelve months ending Jun 30, 2026 was $12.44M, up 89.8% year over year. For fiscal 2025 it was $9.80M, up 172.1% from the year before. The highest annual figure on record is $9.80M in fiscal 2025.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$9.80M+172.1%
FY2024Dec 31, 2024$3.60M+8.9%
FY2023Dec 31, 2023$3.31M+23.8%
FY2022Dec 31, 2022$2.67M+71.0%
FY2021Dec 31, 2021$1.56M+540.1%
FY2020Dec 31, 2020$244.16K+434.8%
FY2019Dec 31, 2019$45.65K-98.6%
FY2017Dec 31, 2017$3.32M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$3.63M+76.9%
Q1 FY2026Mar 31, 2026$3.43M+44.6%
Q4 FY2025Dec 31, 2025$3.10M+194.9%
Q3 FY2025Sep 30, 2025$2.28M+111.3%
Q2 FY2025Jun 30, 2025$2.05M+249.0%
Q1 FY2025Mar 31, 2025$2.37M+168.2%
Q4 FY2024Dec 31, 2024$1.05M+26.2%
Q3 FY2024Sep 30, 2024$1.08M+42.3%
Q2 FY2024Jun 30, 2024$587.50K-6.0%
Q1 FY2024Mar 31, 2024$885.30K-18.9%
Q4 FY2023Dec 31, 2023$832.39K+35.8%
Q3 FY2023Sep 30, 2023$758.76K+1.8%
Q2 FY2023Jun 30, 2023$625.10K-14.0%
Q1 FY2023Mar 31, 2023$1.09M+85.8%
Q4 FY2022Dec 31, 2022$613.07K-39.1%
Q3 FY2022Sep 30, 2022$745.51K+186.7%
Q2 FY2022Jun 30, 2022$726.69K+203.7%
Q1 FY2022Mar 31, 2022$587.57K–
Q4 FY2021Dec 31, 2021$1.01M–
Q3 FY2021Sep 30, 2021$260.00K–
Q2 FY2021Jun 30, 2021$239.28K–

More Quoin Pharmaceuticals figures

See a number that looks wrong?